CORT Corcept Therapeutics Incorporated.

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 4, 2020. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information

To participate, dial 1-800-353-6461 from the United States or 1-334-323-0501 internationally approximately ten minutes before the start of the call. The passcode will be 6800706.

A replay will be available through August 18, 2020 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 6800706.

About Corcept Therapeutics Incorporated

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has discovered a large portfolio of proprietary compounds, that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.

CONTACT:

Christopher S. James, MD

Director, Investor Relations

Corcept Therapeutics

650-684-8725



 

EN
28/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Corcept Therapeutics Incorporated.

Corcept Therapeutics Inc: 3 directors

Three Directors at Corcept Therapeutics Inc sold/sold after exercising options 88,760 shares at between 71.955USD and 72.898USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades...

 PRESS RELEASE

Corcept Therapeutics Announces Second Quarter Financial Results and Pr...

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update MENLO PARK, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2024. Financial Results Revenue of $163.8 million, a 39 percent increase over the same period in 2023Increase in 2024 revenue...

 PRESS RELEASE

Corcept Therapeutics to Announce Second Quarter Financial Results, Pro...

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call MENLO PARK, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking . Upon registering, each participant will receive...

 PRESS RELEASE

Corcept Announces Presentation of Results From Prevalence Phase of CAT...

Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions Results from the CATALYST clinical trial were presented at the American Diabetes Association’s 84th Scientific Sessions at a featured plenary session titled: “Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes” With 1,055 patients enrolled, CATALYST is the largest and most rigorous study ever conducted to assess the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetesResults demonstrate a hyperco...

 PRESS RELEASE

Corcept Therapeutics Announces Presentations of Results of Pivotal Pha...

Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome) MENLO PARK, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the results from GRACE, the Phase 3 trial of its proprietary selective cortisol modulator re...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch